RxDoctor Payments Data

John Steinberg, DPM

Foot & Ankle Surgery · Washington, DCNPI 1265432009

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (56.4%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 34 manufacturers reported payments, led by Integra Lifesciences Corporation at 55.5% of the total. 2025 is the largest year on record at $95,103, more than ten times the $1,454 reported in 2019. Among foot & ankle surgery clinicians in DC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$166,357in general payments, 2019–2025

Across 264 payments — averaging $630.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Integra Lifesciences Corporation$92K
  • Solventum Corporation$27K
  • Medline Industries LP$24K
  • Medshape, Inc.$8K
  • Polynovo North America LLC$4K
  • Averitas Pharma Inc.$3K
  • plus $9K from 28 others

What the payments were for

  • Consulting fees$93,81056%
  • Speaking & faculty fees$31,11319%
  • Travel & lodging$26,02316%
  • Food & beverage$6,4014%
  • Education$220%
  • Other$8,9885%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$166,357 in reported general payments places this provider in the 95th percentile of 23 foot & ankle surgery providers in District of Columbia.

See all foot & ankle surgery providers in District of Columbia

Medicare billing

Part B allowed, 2024
$199,760
Medicare patients
396
Services billed
1,718

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Neomycin-Polymyxin-HydrocortNeomycin/Polymyxin B/Hydrocort17$957
Diclofenac Sodium34$949
Pregabalin34$705
Ammonium Lactate22$643
Terbinafine Hcl50$480
Ciclopirox11$342
Doxycycline Hyclate29$252
Clotrimazole11$138
Gabapentin13$87
Oxycodone Hcl18$82
Meloxicam50$79
Tramadol Hcl16$36

Paid to pharmacies, not to this prescriber.

Other foot & ankle surgery in Washington

See the full list for District of Columbia

Where these figures come from

Is this you, or does something look wrong? →